Datavant vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
Datavant is the largest health data ecosystem connecting healthcare organizations through privacy-preserving tokenization that enables real-world data linkage across systems.
About
Datavant is a health data company founded in 2017 that has built the largest real-world health data ecosystem in the United States through its privacy-preserving data tokenization technology. The company's platform enables healthcare organizations including hospitals, insurers, pharmaceutical companies, and research institutions to link patient records across databases without sharing identifying information, using consistent de-identified tokens that allow data to be joined securely. Datavant raised over $600M and expanded significantly through its merger with Ciox Health, combining Datavant's tokenization technology with Ciox's medical record retrieval operations. The company serves life sciences companies that need real-world evidence from claims, EHR, and specialty data sources, payers managing population health programs, and health systems that want to generate revenue from their patient data while maintaining privacy compliance. Datavant's network effect grows as more organizations adopt the tokenization standard, making the ecosystem more valuable for every participant. The platform has become critical infrastructure for real-world evidence generation in pharmaceutical development and health economics research.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.